Physician profile
Ruth C Pinter
NPI 1417116732
$3,132.73
in general payments reported to CMS, 2019-2025
21 companies · $1,239 in 2025
The $1,239 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.15 · 2022: $363 · 2023: $732 · 2024: $731 · 2025: $1,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $1,346.35 | 2023-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $433.29 | 2021-2025 | Belbuca, Xtampza |
| Novartis Pharmaceuticals Corporation | $409.96 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.15 | 2021-2025 | Relistor |
| Pfizer INC. | $112.77 | 2023-2025 | |
| Virtus Pharmaceuticals LLC | $66.73 | 2024-2025 | Levorphanol Tartrate |
| Boston Scientific Corporation | $55.01 | 2021-2022 | |
| Abbvie INC. | $54.02 | 2023 | |
| Upsher-Smith Laboratories LLC | $49.54 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $44.07 | 2025 | |
| Medtronic, INC. | $39.52 | 2023 | Mazor X System, Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $36.30 | 2022 | |
| Lilly USA, LLC | $36.09 | 2022 | |
| Ibsa Pharma INC. | $23.82 | 2023 | Tirosint, Licart |
| Spr Therapeutics, INC | $21.71 | 2023 | Sprint Pns System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $21.46 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $20.45 | 2021 | |
| Amneal Pharmaceuticals LLC | $16.19 | 2022 | |
| Abbott Laboratories | $13.25 | 2024 | Proclaim |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Stimwave Technologies Incorporated | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Pinter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.